- Raised $7M Seed round, Apr 2025
About
ImmuneWalk Therapeutics is a clinical-stage biotechnology company dedicated to developing novel therapies for immune-inflammatory diseases. The company's approach is based on the discovery of a new adhesion checkpoint that selectively regulates the migration of myeloid cells (monocytes and neutrophils) into inflamed tissues. Their lead candidate, IW-601, is a proprietary monoclonal antibody engineered to prevent these immune cells from entering inflamed tissues, thereby reducing immune-driven inflammation without depleting blood cells. Preclinical studies have shown disease-modifying activity in models of multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease, and metabolic dysfunction-associated steatohepatitis (MASH). The company is currently conducting the POINTGUARD Phase 1 clinical trial, which has met all primary and secondary endpoints, demonstrating positive safety, pharmacokinetics, and mechanistic validation. ImmuneWalk Therapeutics plans to initiate a Phase 2 study in Behçet's disease in the second half of 2027.
Funding history · 1 round · $7.0M total
Q&A
- What is ImmuneWalk Therapeutics' primary focus?
- ImmuneWalk Therapeutics is a clinical-stage company focused on developing novel therapies for chronic inflammatory diseases by preventing myeloid cells from entering inflamed tissue.
- When was ImmuneWalk Therapeutics founded?
- ImmuneWalk Therapeutics was founded in October 2023.
- How much funding has ImmuneWalk Therapeutics raised to date?
- ImmuneWalk Therapeutics has raised a total of $7,000,000.
- When did ImmuneWalk Therapeutics complete its last funding round?
- ImmuneWalk Therapeutics completed a funding round in May 2025, raising $7,000,000.
- What is the current employee count for ImmuneWalk Therapeutics?
- ImmuneWalk Therapeutics has 1-10 employees.
- Who are the co-founders of ImmuneWalk Therapeutics?
- The co-founders of ImmuneWalk Therapeutics are Prof Dror Harats (CEO), Sam Backenorth (CFO), and Erez Feige (COO).
- What is ImmuneWalk Therapeutics' core technology?
- ImmuneWalk Therapeutics utilizes Monocyte Targeting Technology (MTT) to selectively block the migration of monocytes from the bloodstream into inflamed tissues.
- What is the current product stage of ImmuneWalk Therapeutics' solution IW-601?
- ImmuneWalk Therapeutics is advancing its solution, IW-601, to a Phase 1 clinical trial.
Team · 3
Sectors & technology
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | immunewalk.com/ |
|---|---|
| X / Twitter | immunewalk |
Identifiers & details
| Founded | 2023-10 |
|---|---|
| Employees (exact) | 7 |
Radar intelligence
Patents
| EPO | 5 |
|---|
Web history (Wayback)
| Domain | immunewalk.com |
|---|
Certificate / subdomain footprint
| Subdomains | 2 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 516880986 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2023-10-19 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | yes |
| Active charges / liens | 0 |
| Registry events | 1 — violation (1) |
| Registered address | המגשימים 20 פתח תקווה |
Recent registry events
| Date | Event |
|---|---|
| 2026-06-25 | עדכון הפרה |